ReviewEuropean journal of medical research2025
Natural and engineered extracellular vesicles in vascular diseases: a focus on therapeutic effects, challenges and prospective.
Review in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated Epidemiological and Extracellular Vesicle Profiling Identifies miR-126-3p, miR-21-5p, miR-92a-3p and SNAIL as Candidate Biomarkers of Endothelial Dysfunction and Cardio-Metabolic Risk.International journal of molecular sciences · 2026Article
- Harnessing Natural Extracellular Vesicles to Combat Age-Related Diseases: From Aging Drivers to Therapeutic Opportunities.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular diseases (VD), such as cardiovascular diseases, cerebrovascular diseases, and diabetic diseases, originate from numerous pathophysiological changes and remain a serious public health concern. Extracellular vesicles (EVs) produced by cells contribute to regulating VD either dangerously or beneficially. The term EVs refers to the heterogeneous population of vesicles, such as exosomes and microvesicles that participate in cell communication during VD. EVs from different cells, especially those of stem cells, show great promise in the improvement of various VD. They can repair cellular damage, enhance and recover cell function, multiply cells, and prevent cell death and inflammation in specific tissues/cells. EVs have the potential to enhance conditions like cardiovascular disease, cerebrovascular disorders, and complications related to diabetes. Furthermore, an increasing amount of evidence indicates that EVs can be altered/loaded to create a drug delivery system for transporting therapeutic agents to cells, improving different VD. Different methods are used to engineer EVs to improve the efficacy of natural EVs. Despite the potential clinical application of EVs, this field facese many problems that need to be addressed. These limitations and challenges have unmasked the unexpected complexity of EVs regulatory mechanisms, and inspiring advances have been achieved.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.